Halper Sadeh Investigates iTeos Therapeutics and WK Kellogg Sales.
PorAinvest
miércoles, 20 de agosto de 2025, 11:30 am ET1 min de lectura
ITOS--
iTeos Therapeutics Acquisition
Halper Sadeh LLC is investigating iTeos Therapeutics' acquisition by Concentra Biosciences, which has proposed a transaction valued at $10.047 per share, plus a contingent value right [1]. The contingent value right entitles shareholders to receive 100% of the closing net cash of iTeos in excess of $475 million and 80% of any net proceeds from the disposition of certain product candidates within six months following the closing. Shareholders of iTeos are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options.
WK Kellogg Co Acquisition
Kahn Swick & Foti, LLC is investigating the proposed sale of WK Kellogg Co to The Ferrero Group, which offers $23.00 per share in cash [2]. The firm is seeking to determine if the consideration and the process leading to the transaction are adequate and whether the offer undervalues the company. Shareholders of WK Kellogg are advised to reach out to Kahn Swick & Foti, LLC for further information.
Both firms are handling these cases on a contingent fee basis, meaning shareholders will not be responsible for out-of-pocket legal fees or expenses. Shareholders are encouraged to contact the respective law firms to discuss their legal rights and options.
References
[1] https://www.morningstar.com/news/pr-newswire/20250820ny55460/shareholder-investigation-halper-sadeh-llc-investigates-itos-and-klg-on-behalf-of-shareholders
[2] https://www.globenewswire.com/news-release/2025/08/20/3136089/6713/en/ITEOS-THERAPEUTICS-INVESTOR-ALERT-BY-THE-FORMER-ATTORNEY-GENERAL-OF-LOUISIANA-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-iTeos-Therapeutics-.html
KLG--
Halper Sadeh LLC is investigating iTeos Therapeutics and WK Kellogg Co for potential violations of federal securities laws and/or breaches of fiduciary duties to shareholders. iTeos is being acquired by Concentra Biosciences for $10.047 per share, while Kellogg is being acquired by Ferrero Group for $23.00 per share. Shareholders of these companies can click on the provided links to learn more about their rights and options.
Two prominent investor rights law firms, Halper Sadeh LLC and Kahn Swick & Foti, LLC, have initiated investigations into the proposed acquisitions of iTeos Therapeutics, Inc. (NASDAQ: ITOS) by Concentra Biosciences, LLC, and WK Kellogg Co (NYSE: KLG) by The Ferrero Group. The investigations aim to assess whether the transactions comply with federal securities laws and if the consideration offered to shareholders is adequate.iTeos Therapeutics Acquisition
Halper Sadeh LLC is investigating iTeos Therapeutics' acquisition by Concentra Biosciences, which has proposed a transaction valued at $10.047 per share, plus a contingent value right [1]. The contingent value right entitles shareholders to receive 100% of the closing net cash of iTeos in excess of $475 million and 80% of any net proceeds from the disposition of certain product candidates within six months following the closing. Shareholders of iTeos are encouraged to contact Halper Sadeh LLC to discuss their legal rights and options.
WK Kellogg Co Acquisition
Kahn Swick & Foti, LLC is investigating the proposed sale of WK Kellogg Co to The Ferrero Group, which offers $23.00 per share in cash [2]. The firm is seeking to determine if the consideration and the process leading to the transaction are adequate and whether the offer undervalues the company. Shareholders of WK Kellogg are advised to reach out to Kahn Swick & Foti, LLC for further information.
Both firms are handling these cases on a contingent fee basis, meaning shareholders will not be responsible for out-of-pocket legal fees or expenses. Shareholders are encouraged to contact the respective law firms to discuss their legal rights and options.
References
[1] https://www.morningstar.com/news/pr-newswire/20250820ny55460/shareholder-investigation-halper-sadeh-llc-investigates-itos-and-klg-on-behalf-of-shareholders
[2] https://www.globenewswire.com/news-release/2025/08/20/3136089/6713/en/ITEOS-THERAPEUTICS-INVESTOR-ALERT-BY-THE-FORMER-ATTORNEY-GENERAL-OF-LOUISIANA-Kahn-Swick-Foti-LLC-Investigates-Adequacy-of-Price-and-Process-in-Proposed-Sale-of-iTeos-Therapeutics-.html
Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios